The Effect of Metformin on Adolescents with Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Wei LiuXiao-Jie YangPublished in: International journal of endocrinology (2016)
Background. The effect of metformin in combination with insulin in adolescents with type 1 diabetes (T1DM) is controversial. Methods and Results. The PubMed and EMBASE online databases were searched. Five double-blind randomized controlled trials (RCTs) that included 301 adolescents with T1DM were identified. Metformin plus insulin was associated with reduced hemoglobin A1C levels, total daily insulin dosage, body mass index (BMI), and body weight. However, the subgroup analysis demonstrated that HbA1c levels were not significantly changed in overweight/obese adolescents and were significantly reduced in the general patients. On the contrary, BMI and body weight were significantly reduced in overweight/obese adolescents but not in the general patients. Metformin was associated with higher incidence of adverse events. Conclusions. Among adolescents with T1DM, administering adjunctive metformin therapy in addition to insulin was associated with improved HbA1c levels, total daily insulin dosage, BMI, and body weight. However, there may be differences in the effects of this regimen between overweight/obese and nonobese adolescents. The risk of an adverse event may be increased with metformin treatment. These results provide strong evidence supporting future high-quality, large-sample trials.
Keyphrases
- body weight
- physical activity
- type diabetes
- young adults
- body mass index
- weight loss
- glycemic control
- weight gain
- end stage renal disease
- adipose tissue
- newly diagnosed
- metabolic syndrome
- chronic kidney disease
- ejection fraction
- randomized controlled trial
- clinical trial
- prognostic factors
- bariatric surgery
- stem cells
- healthcare
- double blind
- health information
- social media
- combination therapy
- big data
- obese patients
- patient reported
- cell therapy
- study protocol
- smoking cessation
- patient reported outcomes
- deep learning
- replacement therapy
- phase ii